Table 1.
Leading vaccines for COVID-19 (Updated Feb. 19, 2021).
| Vaccine name | Developers | Efficacy | Phase | Dose | Approved or emergency use |
|---|---|---|---|---|---|
| Comirnaty | Pfizer; BioNTech | 95% | Phase 2/3 | 2 doses, 3 weeks apart | Argentina, Canada, Chile, Costa Rica, Ecuador, Jordan, Kuwait, Mexico, Panama, Singapore, Bahrain, Saudi Arabia, Switzerland, European Union |
| mRNA-1273 | Moderna; National Institutes of Health | 94.5% | Phase 3 | 2 doses, 4 weeks apart | United States of America, Canada, Israel and European Union |
| Sputnik V | Gamaleya Research Institute; Health Ministry of the Russian Federation | 91.4% | Phase 3 | 2 doses, 3 weeks apart | Russia, Bolivia, Argentina, Algeria, Serbia, Belarus. |
| AZD1222 | University of Oxford; AstraZeneca | 62% to 90% | Phase 2/3 | 2 doses, 4 weeks apart | Argentina, India, Morocco, Britain, Mexico, El Salvador, Dominican Republic |
| BBIBP-CorV | Sinopharm | 79.34% | Phase 3 | 2 doses, 3 weeks apart | China, Jordan, Egypt, Bahrain, United Arab Emirates |
| CoronaVac | Sinovac | < 78% | Phase 3 | 2 doses, 2 weeks apart | China |
| Convidecia | CanSino | Unknown | Phase 3 | Single dose | China |
| Ad26.COV2.S | Johnson & Johnson | Unknown | Phase 3 | Single dose | |
| EpiVacCorona | Vector Institute | Unknown | Phase 3 | 2 doses, 3 weeks apart | Russia |
| NVX-CoV2373 | Novavax | Unknown | Phase 3 | 2 doses, 3 weeks apart | |
| Sinopharm-Wuhan | Unknown | Phase 3 | Unknown | China; United Arab Emirates | |
| Covaxin | Bharat Biotech | Unknown | Phase 3 | 2 doses, 4 weeks apart | India |
Source: Zimmer, Corum and Wee [38].